This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Headquartered in Natick, MA and founded in 1979, Boston Scientific Corporation manufactures medical devices and products used in various interventional medical specialties worldwide. The company has adopted the organic as well as inorganic routes for success. Boston Scientific currently has 3 global reportable segments viz. Cardiovascular (39.6% of total revenue in 2019; up 10% organically from 2018), Rhythm and Neuro (28.1%; up 1%) and MedSurg (30.2%; up 10.6%).
The Most Spectacular Earnings Charts This Week
by Tracey Ryniec
Investors aren't spooked in these stocks. They have great earnings track records and shares are trading near their highs.
BAX vs. BSX: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
BAX vs. BSX: Which Stock Is the Better Value Option?
Will Boston Scientific's (BSX) Q3 Earnings Reflect Overall Gain?
by Zacks Equity Research
We are optimistic about the IC business that will help Boston Scientific (BSX) maintain impressive global growth, owing to an innovative portfolio and robust commercial teams.
Boston Scientific (BSX) Q3 Earnings Preview: What to Expect
by Zacks Equity Research
Boston Scientific (BSX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Invest in Boston Scientific Stock Now
by Zacks Equity Research
Boston Scientific (BSX) is coming up with better-than-expected earnings and revenue performances on the back of growth across all business lines and geographies.
Why Boston Scientific (BSX) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
Boston Scientific (BSX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Boston Scientific Grows on Acquisitions, Product Launches
by Zacks Equity Research
Boston Scientific's (BSX) strategy to extend its existing portfolio through inorganic growth profile has been advancing well. Further, this should help aid the company's top line in the long term.
Baxter (BAX) Collaborates With USC CBC to Digitize Healthcare
by Zacks Equity Research
Baxter's (BAX) efforts to digitize healthcare solutions are likely to fortify its foothold in the highly competitive MedTech industry.
Boston Scientific Thrives in Urology on New LithoVue Empower
by Zacks Equity Research
Boston Scientific's (BSX) combination of LithoVue Empower and LithoVue Single-Use Digital Ureteroscope will put the whole stone manipulation procedure in the operating surgeon's hands.
Boston Scientific's FDA Nod for Eluvia Stent Expands PI Suite
by Zacks Equity Research
Boston Scientific's (BSX) PMA approval for Eluvia Drug-Eluting Vascular Stent System will help boost the top line at the PI business.
Boston Scientific to Boost MedSurg Unit Via Augmenix Buyout
by Zacks Equity Research
Boston Scientific (BSX) continues to adopt organic as well as inorganic means to boost top line.
New Buyouts Aid Boston Scientific Amid Dull Pacemaker Sales
by Zacks Equity Research
Boston Scientific (BSX) continues to adopt organic as well as inorganic routes for success. However, sluggish global pacemaker sales continue to disappoint.
Boston Scientific (BSX) Up 0.1% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Boston Scientific (BSX) reported earnings 30 days ago. What's next for the company? We take a look at earnings estimates for some clues.
Boston Scientific to Expand Within PI Via VENITI Buyout
by Zacks Equity Research
Presence of venous obstructive disease visibly grows across the globe, indicating huge prospects for Boston Scientific (BSX) in the treatment market.
Medical Product Stock Earnings on Aug 6: CAH, HSIC & More
by Zacks Equity Research
The Medical product market gains momentum owing to the recent two-year suspension of the controversial 2.3% Medical Device tax.
Boston Scientific (BSX) Beats on Q2 Earnings, Margins Down
by Zacks Equity Research
Boston Scientific (BSX) registers steady growth across all business lines and geographies in Q2.
Boston Scientific (BSX) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Boston Scientific (BSX) delivered earnings and revenue surprises of 20.59% and 1.02%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Boston Scientific (BSX) Beats on Q2 Earnings and Revenues
by Zacks Equity Research
Boston Scientific (BSX) has posted impressive results by delivering revenue growth across all segments in Q2.
Medical Product Earnings Lineup for Jul 25: TMO, BSX & More
by Zacks Equity Research
The Medical product market further gains momentum on the back of a recent two-year suspension of the controversial 2.3% Medical Device tax.
What's in the Cards for Zimmer Biomet (ZBH) in Q2 Earnings?
by Zacks Equity Research
Focusing on the thrust areas like quality correction, supply recovery efforts and product introductions, Zimmer Biomet (ZBH) is expected to retain robust top-line numbers within its S.E.T. arm.
LZAGY vs. BSX: Which Stock Is the Better Value Option?
by Zacks Equity Research
LZAGY vs. BSX: Which Stock Is the Better Value Option?
AngioDynamics (ANGO) Q4 Performance Dull, Competition Rife
by Zacks Equity Research
AngioDynamics' (ANGO) fourth-quarter performance dull; stiff competition a serious concern.
Top Research Reports for AT&T, Home Depot & Cisco
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including AT&T (T), Home Depot (HD) and Cisco (CSCO).
Thermo Fisher (TMO) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
Thermo Fisher (TMO) continues with its impressive performance momentum across analytical instrument businesses witnessing escalating global demand.
Can Strategic Alliances Aid LabCorp's (LH) Q2 Earnings?
by Zacks Equity Research
LabCorp (LH) is expected to gain traction from a solid LabCorp Diagnostics segment in Q2, courtesy of a favorable price, mix, tuck-in acquisitions and organic volume.